Chieregato G C, Leoni A
Acta Derm Venereol. 1986;66(4):321-4.
In psoriatic arthropathy the data obtained after two years of etretinate treatment in 20 adult male patients, are reported. The beneficial effects of the drug on the objective symptoms are accompanied by an improvement in the biohumoral parameters evaluated. The dose was 1 mg/kg/day for one month, with subsequent adjustments in relation to the results obtained with a maintenance dose of 25 mg/day, or where possible, 10 mg/day, or on alternate days, for a maximum period of 25 months. The side effects appeared to be of an acceptable degree of severity. The authors consider etretinate one of the drugs of first choice in the treatment of psoriatic arthropathy.
本文报告了20例成年男性银屑病关节炎患者接受依曲替酯治疗两年后所获得的数据。该药物对客观症状的有益作用伴随着所评估的生物体液参数的改善。剂量为1mg/kg/天，持续1个月，随后根据维持剂量25mg/天（或在可能的情况下10mg/天，或隔日服用）所取得的结果进行调整，最长治疗期为25个月。副作用的严重程度似乎在可接受范围内。作者认为依曲替酯是治疗银屑病关节炎的首选药物之一。
